NASDAQ:MYNZ
Mainz Biomed B.V. Stock News
$0.750
-0.130 (-14.76%)
At Close: May 01, 2024
What Makes Mainz Biomed NV (MYNZ) a New Buy Stock
01:01pm, Friday, 08'th Mar 2024
Mainz Biomed NV (MYNZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Mainz Biomed N.V. MYNZ recently released the results of its ColoFuture study in the American healthcare market.
Mainz Biomed's Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
08:01am, Wednesday, 29'th Nov 2023
BERKELEY, Calif. and MAINZ, Germany, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
08:01am, Monday, 20'th Nov 2023
BERKELEY, Calif. and MAINZ, Germany, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Why Is Mainz Biomed (MYNZ) Stock Moving Today?
08:40am, Wednesday, 01'st Nov 2023
Mainz Biomed (NASDAQ: MYNZ ) stock is on the move Wednesday after the molecular genetics cancer diagnostic company shared results from a colorectal cancer screening test campaign. The company held th
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
08:01am, Wednesday, 27'th Sep 2023
Clinical trial evaluating the Company's novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and advanced adenoma sensitivity of 81% Pulsus Group's 4th I
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference
03:01am, Wednesday, 20'th Sep 2023
BERKELEY, Calif. and MAINZ, Germany, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
03:01am, Tuesday, 29'th Aug 2023
Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Studies this September and in Q4 Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Stu
Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23
03:01am, Tuesday, 21'st Mar 2023
BERKELEY, Calif. and MAINZ, Germany, March 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in
Mainz Biomed: A Long-Term Bet Relying On Expanded Testing
02:16am, Sunday, 30'th Oct 2022
Mainz Biomed is a German developer of genetic tests for various diseases, primarily cancer. At the moment, the company has one main product, ColoAlert, a colorectal cancer test that is so far only app
Mainz Biomed to Present at the H.C. Wainwright Annual Global Investment Conference
03:01am, Thursday, 01'st Sep 2022
BERKELEY, Calif. and MAINZ, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing
Mainz Biomed to Participate in H.C. Wainwright Global Investment Conference and Equity Forum German Spring Conference
03:01am, Tuesday, 17'th May 2022
BERKELEY, Calif. and MAINZ, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in
Why Mainz Biomed Stock Is Crashing Today
12:36pm, Wednesday, 26'th Jan 2022
The molecular genetics diagnostic company announced the pricing of a follow-on stock offering.
Mainz Biomed: Sharp Appreciation In Value Since IPO
06:17am, Wednesday, 26'th Jan 2022
Mainz Biomed has filed Form F-1 to raise ~$41 million gross proceeds from 1.5M shares.
Mainz Biomed to Present at the H.C. Wainwright Bioconnect Virtual Conference
03:01am, Tuesday, 11'th Jan 2022
BERKELEY, Calif. and MAINZ, Germany, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing i
